- Ocumetics Technology (TSXV:OTC) has notched a milestone in optimizing its vision correction technology called the Ocumetics Accommodating Lens
- The company has modified its lens design five times over the past two years to reach the final lens configuration version 10.5
- Version 10.5 has been tested in vitro in an animal model and will be used in upcoming human trials
- Shares of Ocumetics Technology are unchanged at C$0.34
Ocumetics Technology (TSXV:OTC) has notched a breakthrough in optimizing its vision correction technology, called the Ocumetics Accommodating Lens.
In a news release, the Calgary-based company – which is focused on ophthalmic innovation – said that over the past two years, it has designed the lens five times to reach the final lens configuration version 10.5.
The Ocumetics Accommodating Lens is an expandable intraocular lens that fits within the natural lens compartment of the eye, potentially eliminating the need for corrective lenses. It is designed to allow the eye’s natural muscle activity to seamlessly shift focus from distance to intermediate to near.
The company said this version of the lens has been tested in vitro in animal trials and will now proceed to human trials, which Ocumetics Technology anticipates beginning in Q1 2024 in the Dominican Republic.
“Our success in optimizing the lens design underscores our dedication to understanding the needs of patients and listening to our valued investigators and advisors,” Dean Burns, CEO of Ocumeticss Technology, said in a statement. “This iterative process reflects our commitment to delivering on our promise of enhanced vision.”
Ocumetics Technology is an innovator in the field of ophthalmic technology, dedicated to developing and commercializing advanced vision correction solutions that enhance the quality of life for individuals worldwide.
Shares of Ocumetics Technology are unchanged at C$0.34.
Join the discussion: Find out what everybody’s saying about this stock on the Ocumetics Technology Bullboard, and check out the rest of Stockhouse’s stock forums and message boards.
The material provided in this article is for information only and should not be treated as investment advice. For full disclaimer information, please click here.